Zum Inhalt springen

Nur-Lesen-Fassung: Das Forschungsinformationssystem (FIS) ist aus Sicherheitsgründen vorübergehend durch diese Nur-Lesen-Fassung ersetzt. Alle öffentlichen Inhalte und Volltexte sind weiterhin abrufbar; Anmeldung, Bearbeitung, Einreichung und Statistiken stehen nicht zur Verfügung. Bei Fragen: fis@uni-bamberg.de

Start › Publikationen › The PROVIT Study : Effects of Multispecies Probiotic Add-on Treatment on Metabolomics in Major Depressive Disorder ; A Randomized, Placebo-Controlled Trial

Publikation

The PROVIT Study : Effects of Multispecies Probiotic Add-on Treatment on Metabolomics in Major Depressive Disorder ; A Randomized, Placebo-Controlled Trial

Kreuzer, Kathrin; Reiter, Alexandra; Birkl-Töglhofer, Anna-Maria; u. a. (2025): The PROVIT Study : Effects of Multispecies Probiotic Add-on Treatment on Metabolomics in Major Depressive Disorder ; A Randomized, Placebo-Controlled Trial, in: Bamberg: Otto-Friedrich-Universität, S. 1–19.

Details

Fakultät/Lehrstuhl
Autorin(nen)/Autor(en)
Kreuzer, Kathrin; Reiter, Alexandra; Birkl-Töglhofer, Anna-Maria; Dalkner, Nina; Mörkl, Sabrina; Mairinger, Marco; Fleischmann, Eva; Fellendorf, Frederike T.; Platzer, Martina; Lenger, Melanie; ORCID iDFärber, Tanja; Seidl, Matthias; Birner, Armin; Queissner, Robert; Mendel, Lilli-Marie; Maget, Alexander; Kohlhammer-Dohr, Alexandra; Häussl, Alfred; Wagner-Skacel, Jolana; Schöggl, Helmutt; Amberger-Otti, Daniela; Painold, Annamaria; Lahousen-Luxenberger, Theresa; Leitner-Afschar, Brigitta; Haybaeck, Johannes; Habisch, Hansjörg; Madl, Tobias; Reininghaus, Eva; Bengesser, Susanne A.
Verlagsangabe
Otto-Friedrich-Universität : Bamberg
Erscheinungsjahr
2025
Quelle/Weitere Ausgabe
Metabolites, Basel: MDPI, 2022, Jg. 12, Nr. 8, S. 1–19, ISSN: 2218-1989
Jahr der Erstpublikation
2022
Sprache(n)
Englisch
Lizenz
URN
Abstract

The gut–brain axis plays a role in major depressive disorder (MDD). Gut-bacterial metabolites are suspected to reduce low-grade inflammation and influence brain function. Nevertheless, randomized, placebo-controlled probiotic intervention studies investigating metabolomic changes in patients with MDD are scarce. The PROVIT study (registered at clinicaltrials.com NCT03300440) aims to close this scientific gap. PROVIT was conducted as a randomized, single-center, double-blind, placebo-controlled multispecies probiotic intervention study in individuals with MDD (n = 57). In addition to clinical assessments, metabolomics analyses (1H Nuclear Magnetic Resonance Spectroscopy) of stool and serum, and microbiome analyses (16S rRNA sequencing) were performed. After 4 weeks of probiotic add-on therapy, no significant changes in serum samples were observed, whereas the probiotic groups’ (n = 28) stool metabolome shifted towards significantly higher concentrations of butyrate, alanine, valine, isoleucine, sarcosine, methylamine, and lysine. Gallic acid was significantly decreased in the probiotic group. In contrast, and as expected, no significant changes resulted in the stool metabolome of the placebo group. Strong correlations between bacterial species and significantly altered stool metabolites were obtained. In summary, the treatment with multispecies probiotics affects the stool metabolomic profile in patients with MDD, which sets the foundation for further elucidation of the mechanistic impact of probiotics on depression.

Freie Schlagwort(e)
depression
gut–brain-axis
probiotics
metabolomics
NMR spectroscopy
butyrate
randomized controlled trial
DDC-Klassifikation
150 Psychologie
RVK-Klassifikation
CU 1000
Dokumenttyp
Artikel in einer Zeitschrift / Postprint
URI
Datum der Freischaltung
23.07.2025

Permalink: https://fis.uni-bamberg.de/handle/uniba/108277 · Daten als JSON · Zitieren: BibTeX · RIS

Datenstand: 15.11.2026

Eingeschränkter Lesezugriff: Anmeldung, Bearbeitung und Einreichung sind vorübergehend deaktiviert.